Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Catabasis Pharmaceuticals to Present at Upcoming Investor and Industry Conferences

Published: Thursday, March 29, 2012
Last Updated: Thursday, March 29, 2012
Bookmark and Share
Company announced that Michael Jirousek, Ph.D., chief scientific officer and co-founder of Catabasis, will present at the upcoming industry conferences listed below.

-- Needham & Company’s 11th Annual Healthcare Conference, being held April 3-4 at the New York Palace Hotel in New York City. Dr. Jirousek will give a company presentation at 3:40 p.m. on Tuesday, April 3. This conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in sectors such as biotechnology, specialty pharmaceuticals, diagnostics and medical technology.

-- 2nd Diabetes Summit, being held April 19-20 at the Hyatt Harborside in Boston. Dr. Jirousek will present an overview of CAT-1004 as a novel new chemical entity for treating type 2 diabetes in the session “Clinical Drug Development in Diabetes” at 4:05 p.m. on Thursday, April 19. This conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.

-- Future Leaders in the Biotech Industry, being held April 20 at the Millennium Broadway Hotel & Conference Center in New York City. Dr. Jirousek will give a presentation on Catabasis’ novel approach to drug development at 3 p.m. The presentation will feature an overview of the company, proprietary chemistry platform and promising pipeline, including CAT-1004. This conference will showcase companies best positioned to provide market leadership and will continue to emphasize fresh investment opportunities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!